AGP Executive Report
Last update: 6 hours agoFDA Pushes Early-Cancer Gains: The agency expanded AstraZeneca’s Enhertu for HER2-positive early breast cancer, adding new neoadjuvant and adjuvant indications—another step toward “more patients” getting curative chances. Hypertension Gets a First-in-Class Option: FDA approved Baxfendy (baxdrostat), the first aldosterone synthase inhibitor for adults with uncontrolled hypertension on other meds, signaling fresh commercial and development interest in a long-stagnant category. Alzheimer’s Drug Math Under Fire: A research letter warns a statistical method used to support a new Alzheimer’s-drug class can massively overstate efficacy—reporting a 29x inflation risk. Cybersecurity Alarm: Microsoft disclosed an actively exploited Exchange zero-day, but customers still lack a patch days later. Media & Culture: Marvel continues reshuffling leadership as Dan Buckley exits and Brad Winderbaum takes broader creative oversight; ProPublica names 11 journalists for its investigative editor training. Local Life: A Norwich-area “Heritage Night” pairs a bookstore, coffee, and a local history podcast for May 28.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.